Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases

Authors: John A. Snowden, Manuela Badoglio, Myriam Labopin, Sebastian Giebel, Eoin McGrath, Zora Marjanovic, Joachim Burman, John J. Moore, Montserrat Rovira, Nico Wulffraat, Majid Kazmi, Raffaella Greco, Emilian Snarski, Tomáš Kozák, К. И. Киргизов, Tobias Alexander, Peter Bader, Riccardo Saccardi, Dominique Farge - Blood Advances 2017 cited by 216

= .02), allogeneic HSCT use remained low and largely restricted to pediatric practice. Autologous HSCT has evolved into a treatment modality to be considered alongside other modern therapies in severe AD. Center experience, accreditation, interspecialty networking, and national socioeconomic factors are relevant for health service delivery of HSCT in AD.